Aristotle University Of Thessaloniki (AUTH)
Μελέτη της οστεοδυστροφίας μετά από νεφρική μεταμόσχευση
Abstract
dc:descriptionThe aim of the present thesis was to study factors that contribute to osteodystrophy after renal transplantation (RT) and to study ways of treatment of the existing disorders. This study consists of 2 separate stages: prospective study of 33 renal transplant recipients (RTRs), divided in three groups depending on the administration of preventive anti-osteoporotic treatment and retrospective study of risk factors for osteoporosis in 97 RTRs with long-term RT. After successful RT parathormone (PTH) levels were reduced. With alfacalcidol administration greater percentages of patients (60%) achieved normal PTH values. Despite secondary hyperparathyroidism (SHPT) improvement, high PTH levels are still found in 50% of RTRs. Alkaline phosphatase (ALP) levels decreased after RT. We found an increase in calcium levels after RT and mild, often transient, hypercalcemia (25%). Phosphate levels decreased after RT. Hypophosphatemia occurred in more than 30% of the patients the first post-transplant month with a gradual reduction to less than 10% of RTRs after two years. Hypophosphatemia was the result of increased phosphaturia, because TmPO₄/GFR levels were at the lower end of normal range the first two months post-transplantation. From the third post-transplant month TmPO₄/GFR levels were increased. FGF-23 levels were high before transplantation. From the first post-transplant month they were dramatically decreased and at post-transplant month three they were normal. FGF-23 causes phosphaturia after RT and acts synergistically with PTH. We found no correlation between FGF-23 and 1,25(OH)2 vitamin D levels. 25OH vitamin D and 1,25(OH)₂ vitamin D levels were increased during the first post-transplant year. However, about 1 out of 3 RTRs was 25OH vitamin D and 1,25(OH)₂ vitamin D deficient, one year after transplantation. Patients that did not receive preventive treatment for bone loss after RT, presented with BMD loss at the lumbar spine while BMD at the femoral neck was maintained. It was shown that alendronate plus alfacalcidol administration prevented bone loss after RT and was superior to alfacalcidol administration alone and to no treatment. In 97 patients with long-term RT, SHPT persisted in a high percentage. PTH levels correlated with pre-transplant levels and with calcium and ALP. A significant percentage of patients had 25(OH) vitamin D and 1,25(OH)₂ vitamin D insufficiency, while probably its low levels contribute to SHPT persistence. 1,25(OH)₂ vitamin D levels correlated with renal function. Osteopenia/osteoporosis was found frequently. Women had higher rates of osteoporosis and postmenopausal women had lower BMD at the femoral neck. Other factors that were significantly correlated with BMD at the lumbar spine or femoral neck were transplantation duration, body weight, creatinine clearance, cumulative corticosteroid dose and age. Anti-osteoporotic treatment, even late after RT, aids to the slowdown of bone loss.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2012
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Dovas, Spyridon
- Ντόβας, Σπυρίδων
Subjects
dc:subject × 10Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/33148